Association between pulse pressure, systolic blood pressure and the risk of rapid decline of kidney function among general population without hypertension: results from the China health and retirement longitudinal study (CHARLS)

Huai-yu Wang¹², Qin Qin Meng³, Chao Yang⁴, Yafeng Wang³, Guilan Kong¹, Yaohui Zhao⁵, Fang Wang⁴* and Luxia Zhang¹⁴*

Abstract
Background: Association between blood pressure (BP) and kidney function among the middle and old aged general population without hypertension remains unclear.
Methods: Participants aged ≥ 45 years, with complete data in 2011 and 2015 interviews of the China Health and Retirement Longitudinal Study (CHARLS), and without pre-existing hypertension were included. Systolic BP (SBP) was categorized as low (< 120 mmHg), medium (120–129 mmHg), and high (120–139 mmHg). Diastolic BP (DBP) was categorized as low (< 60 mmHg), medium (60–74 mmHg), and high (75–89 mmHg). Pulse pressure (PP) was categorized as normal (< 60 mmHg) and high (≥ 60 mmHg). The outcome was defined as rapid decline of estimated glomerular filtration rate (eGFR, decline ≥ 4 ml/min/1.73 m²/year). BP combination was designed according to the category of SBP and PP. The association between BP components, types of BP combination, and the risk of rapid decline of eGFR was analyzed using multivariate logistic regression models, respectively. Age-stratified analyses were conducted.
Results: Of 4,534 participants included, 695 (15.3%) individuals were recognized as having rapid decline of eGFR. High PP (odds ratio (OR) = 1.34, 95% confidence interval (CI) 1.02–1.75), low SBP (OR = 1.28, 95% CI 1.03–1.59), and high SBP (OR = 1.32, 95% CI 1.02–1.71) were significantly associated with the risk of eGFR decline. Low SBP were associated with a 65% increment of the risk of eGFR decline among participants aged < 55 years. The combination of high SBP and high PP (OR = 1.79, 95% CI 1.27–2.54) and the combination of low SBP and high PP (OR = 3.07, 95% CI 1.24–7.58) were associated with the increased risk of eGFR decline among the middle and old aged general population.

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Chronic kidney disease (CKD) is one of the global public health challenges due to the increasing prevalence, multiple morbidities, and the heavy burden on healthcare system [1–3]. Compared with the high prevalence (around 11%) [4, 5], the awareness of CKD was only 10% [5, 6]. Less than 5% of patients in the early stages of CKD were aware of their disease [7]. Subject to the asymptomatic feature of CKD in early stages, risk recognition and monitor are essential for the early prevention of CKD. As to the population having comorbidities related to CKD, such as hypertension, the control of the comorbidity is the modifiable risk indicator for the decline of kidney function. [8] As to the general population without CKD-related comorbidities, the middle and old aged individuals are generally considered as the target population for risk monitor of CKD since the process of ageing results in the change of structure and function of the kidney [8, 9]. However, the strategy of risk monitor of the general population remains to be explored. The current guidelines on CKD and blood pressure (BP) recommended the routine assessment of eGFR and albuminuria among all patients with hypertension [10–12]. Nevertheless, the presence of eGFR decline and albuminuria means the incidence of CKD and emphasizes the timely treatment of CKD, rather than the early prevention and risk evaluation of CKD. An effective risk indicator for the early risk-recognition of decline in kidney function among the middle and old aged general population is urgently needed. With consideration of the feature of general population who are less tending to receive invasive and costly examination in clinics, an easily accessible, pragmatic and cost-saving approach would be feasible for the risk recognition and monitor among the middle and old aged general population.

There is no doubt that BP is strongly associated with CKD and hypertension, which are cause and consequence to each other [12]. The anti-hypertensive treatment is recommended to preserve the kidney function among patients with CKD [12], and the lower levels of systolic BP (SBP) is associated with the reduced risk of incident CKD among patients with hypertension [13]. Prevention of hypertension is a widely accepted approach to prevent the risk of CKD among the general population without pre-existing hypertension. However, the goal of SBP for different outcomes in different population has been ongoing debate for decades [14]. The BP < 130/80 mmHg was acknowledged as the goal of BP control among patients with hypertension and CKD [10, 12], while the BP goal for kidney function preservation among the general population without hypertension remains under-investigated.

Pulse pressure (PP) is an important BP component, which is calculated by the difference of SBP and diastolic BP (DBP), determined by the arterial and cardiac function, and often used as a surrogate indicator of arterial stiffness [15, 16]. With accumulating evidence, the prognostic significance of PP on cardiovascular disease (CVD) and mortality, especially among the middle and old aged population, were increasingly considered [10] The 2018 European guidelines for arterial hypertension recommended the routine measurement of PP (Class IIb, Level C) [10]. Compared with SBP and DBP, PP showed a stronger association with the cardiac risk among the population with or without CKD [17–23]. Additionally, independent association distinguishing from that of SBP and DBP was reported between PP and cardiovascular disease (CVD), which indicated the potentially unique pathogenesis between PP and CVD [24]. However, regards to the prognostic association of PP and incident CKD, previous studies showed inconsistent results [25–29]. The heterogeneity of the study population and design might lead to the inconsistency since genetic researches demonstrated the substantially ethnic-specific association between genes and BP components [30–32, 32]. Additionally, the improved prognostic significance of the combination of PP and other BP components was observed on predicting the risk of CVD and cardiac mortality among the middle and old aged population [33, 34]. Given the shared pathogenesis of CKD and CVD such as hemodynamic stress and vascular stiffness [35], and considering the easily-accessible and cost-saving feature of BP components, it is worth investigating the association between PP as well as the combination of BP components and the change of kidney function among the middle and old aged general population.

Hence, the present study investigated the association between BP components and the risk of rapid decline of kidney function among the middle and old aged general population without hypertension based on a national cohort study in China. The association between combination of BP components and the risk of rapid decline of kidney function was evaluated. Given the strong

**Conclusion:** Single and combination of high PP and high SBP could be the risk indicators of eGFR decline among the middle and old aged general population.

**Keywords:** Blood pressure, Chronic kidney disease, Risk indicator, Middle and old aged general population
linkage between ageing and the levels of BP, age-stratified analyses were also performed.

**Materials and methods**

**Population**

The present study is based on the China Health and Retirement Longitudinal Study (CHARLS), which is a nationally representative survey of the Chinese population aged 45 years or older and their spouses [36]. A design of four-stage, stratified, cluster sampling was applied. The baseline of CHARLS was conducted between 2011 and 2012 [37]. The blood samples were collected in 2011 and 2015 through a standardized process which was detailed described elsewhere (http://charls.pku.edu.cn/index/en.html).

A total of 9580 participants aged ≥ 45 years and completed the questionnaires, physical examination and blood sample collection in 2011 were included. A total of 1,832 participants diagnosed as hypertension, showing SBP ≥ 140 mmHg, or showing DBP ≥ 90 mmHg were excluded. Another 3,214 participants were excluded due to the absence of serum creatinine (SCr) tests in 2015. Ultimately, 4,534 participants were eligible for the present study (Fig. 1).

This study was approved by the Biomedical Ethics Review Committee of Peking University. All participants gave written informed consent before participation.

**Data collection and specimen**

The demographic, socio-economic, and health status were collected by structured questionnaires with a face-to-face computer-assisted personal interview [36]. The blood samples were stored at −70°C, and measured in a central laboratory in Beijing [37]. Serum creatinine (Scr, mg/dL) was measured by the rate-blanked and compensated Jaffe creatinine method. Glycosylated hemoglobin (HbA1c, %) was measured by boronate affinity HPLC. Low-density lipoprotein (LDL, mg/dL) were measured by enzymatic colorimetric test. Uric acid (UA, mg/dL) were measured by uricase and catalase.

**Variables**

Demographic and clinical data in 2011 was defined as the information at baseline. Age, gender, and the status of smoke and drink (never, past, current) were recorded. Body mass index (BMI, kg/m²) was calculated as weight divided by height squared. Diabetes were defined by self-report history of diabetes, use of hypoglycaemic agents, or a fasting plasma glucose ≥ 7.0 mmol/L. Blood pressure was measured three times (with 45 s apart) using a HEM-7200 electronic monitor (Omron (Dalian) Co., LTD., Dalian, China). The average of three readings was calculated. PP was defined as the differential of SBP and DBP. According to 2018 ESC/ESH Guidelines for the management of arterial hypertension, PP ≥ 60 mmHg was the risk factor of asymptomatic hypertension-mediated organ damage in older adults [10]. Therefore, the present study defined PP category as normal PP (< 60 mmHg) and high PP (≥ 60 mmHg). As to the target range of SBP, the 2018 ESC/ESH Guidelines recommended 130–139 mmHg for most patients and 120–129 mmHg for some patients to enhance the cerebrovascular

---

![Flow chart for participants selection](image)

**Fig. 1** Flow chart for participants selection
The J-shape curve point of DBP among the populations according to the groups of 45–54 years, 55–64 years, and ≥ 65 years were performed. The results were presented as odds ratio (OR)(continuous) and eGFR at baseline (continuous), HbA1c (continuous), LDL (continuous), UA (continuous), and eGFR at baseline (continuous) were adjusted. The results were presented as odds ratio (OR) with 95% confidence interval (CI). All P value were two-tailed and P value < 0.05 was considered to be statistical significance. All analyses were conducted using Stata version 16.0 (Stata Corp LP, College Station, TX, USA).

Results
Population characteristics
The population characteristics at baseline were presented in overall and the levels of eGFR. (Table 1) In total, 4534 participants with the mean age of 57.8 ± 8.4 years were included in the present study. Among them, 1313(39.0%) participants showed the levels of eGFR 60–89 ml/min/1.73m² and 81(1.8%) participants had eGFR < 60 ml/min/1.73m². In contrast to those with eGFR ≥ 90 ml/min/1.73m², participants with lower eGFR were older and with higher proportions of former smoker and former drinkers. (P < 0.05) More participants with eGFR < 60 ml/min/1.73m² had diabetes. (eGFR ≥ 90 ml/min/1.73m² 13.1% vs. eGFR < 60 ml/min/1.73m² 27.1%; P = 0.003) Participants with decreased eGFR showed significantly lower levels of LDL, but higher levels of UA. (P < 0.01).

Higher levels of PP were observed among the participants with higher levels of SBP and lower levels of DBP. (P < 0.001) (Fig. 2) Compared with those having eGFR ≥ 90 ml/min/1.73m², significantly higher levels of PP and SBP were observed among participants with lower levels of eGFR. (P < 0.001) No significant difference of the levels of DBP was observed among participants with different levels of eGFR. (P > 0.05) (Table 1).

Kidney function and BP components
Results of comparisons of kidney function between participants with different category of BP were presented in Table 2. Altogether 695 participants were recognized as rapid decline of eGFR in the present study. Participants with high PP showed significantly lower levels of eGFR at baseline and at the endpoint. (P < 0.001) Much severe annual decline of eGFR and more cases of rapid decline of eGFR were found among participants with high PP. (P < 0.05) Compared with participants with low or medium SBP, participants with high SBP showed significantly lower levels of eGFR both at baseline and at the endpoint. (P < 0.001) Participants with low DBP showed lower levels of eGFR at the endpoint and much severe annual decline of eGFR. (P < 0.05) (Table 2).

Types of BP component and the rapid decline of eGFR
After fully adjusting for the confounders, high PP (OR = 1.34, 95% CI 1.02–1.75), low SBP (OR = 1.28, 95% CI 1.03–1.59), and high SBP (OR = 1.32, 95% CI 1.02–1.71) were significantly associated with the risk of rapid decline of eGFR, respectively. No significant
Association was found between DBP category and the risk of rapid decline of eGFR. \((P > 0.05)\) (Table 3) Results of unadjusted and partly adjusted models were present in Additional file 1.

Age-stratified analyses were performed in the age groups of 45–54 years, 55–64 years and ≥ 65 years, respectively. Low SBP (OR = 1.65, 95% CI 1.13–2.43) was significantly associated with the increased risk of rapid decline of eGFR among participants aged 45–54 years. No significant association was found between types of BP category and the risk of rapid decline of eGFR among the population aged ≥ 55 years. Results of unadjusted and partly adjusted models were present in Additional file 1.

BP combination and the rapid decline of eGFR
According to the present results (Table 3), the strategy of combination of PP and SPB was designed to further explore the association between BP components and the risk of rapid decline of eGFR among the middle and old aged general population without pre-existing hypertension. After adjusting for the confounders, reference to the combination of medium SBP and normal PP, the

### Table 1  Comparison of demographic and clinical characteristics among participants with different levels of eGFR at baseline

| Characteristics | Overall | eGFR (ml/min/1.73m²) | \(\geq 90\) | 60–89 | < 60 | \(P\) value |
|-----------------|---------|----------------------|---------|---|---|-------|
| In Total (n, %) | 4534(100.0) | 3140(69.2) | 1313(39.0) | 81(1.8) | | <0.001 |
| Age (years, mean ± SD) | 57.8 ± 8.4 | 55.9 ± 7.5 | 61.7 ± 8.6 | 68.9 ± 8.4 | | <0.001 |
| Gender (n, %) | 0.530 | | | | | |
| Male | 2092(46.1) | 1439(45.8) | 611(46.5) | 42(51.9) | | |
| Female | 2442(53.9) | 1701(51.2) | 702(53.5) | 39(48.1) | | |
| Smoke (n, %) | 0.019 | | | | | |
| Never | 2805(62.1) | 1966(62.7) | 792(60.7) | 47(58.8) | | |
| Past | 387(8.6) | 240(7.7) | 136(10.4) | 11(13.8) | | |
| Current | 1326(29.4) | 928(29.6) | 376(28.8) | 22(27.5) | | |
| Drink (n, %) | 0.002 | | | | | |
| Never | 2669(58.9) | 1837(58.6) | 777(59.2) | 55(67.9) | | |
| Past | 349(7.7) | 215(6.9) | 126(9.6) | 8(9.9) | | |
| Current | 1512(33.4) | 1084(34.6) | 410(31.2) | 18(22.2) | | |
| BMI (kg/m², mean ± SD) | 23.3 ± 3.7 | 23.3 ± 3.7 | 23.3 ± 3.8 | 22.5 ± 4.4 | | 0.170 |
| Diabetes (n, %) | 0.003 | | | | | |
| No | 3521(86.3) | 2464(86.9) | 1006(85.7) | 51(72.9) | | |
| Yes | 559(13.7) | 372(13.1) | 168(14.3) | 19(27.1) | | |
| HbA1c (% mean ± SD) | 0.311 | | | | | |
| LDL (mg/dl, mean ± SD) | 0.001 | | | | | |
| UA (mg/dl, mean ± SD) | <0.001 | | | | | |
| PP (mmHg, mean ± SD) | <0.001 | | | | | |
| SBP (mmHg, mean ± SD) | <0.001 | | | | | |
| DBP (mmHg, mean ± SD) | 0.836 | | | | | |
| PP category (n, %) | 0.001 | | | | | |
| Normal: < 60 mmHg | 4057(89.5) | 2869(91.4) | 1124(85.6) | 64(79.0) | | |
| High: ≥ 60 mmHg | 477(10.5) | 271(8.6) | 189(14.4) | 17(21.0) | | |
| SBP category (n, %) | <0.001 | | | | | |
| Low: < 120 mmHg | 2398(52.9) | 1728(55.0) | 644(49.1) | 26(32.1) | | |
| Medium: 120–129 mmHg | 1187(26.2) | 827(26.3) | 327(24.9) | 33(40.7) | | |
| High: 130–139 mmHg | 949(20.9) | 585(18.6) | 342(26.1) | 22(27.2) | | |
| DBP category (n, %) | 0.950 | | | | | |
| Low: < 60 mmHg | 531(11.7) | 364(11.6) | 160(12.2) | 7(8.6) | | |
| Medium: 60–74 mmHg | 2502(55.2) | 1733(55.2) | 725(55.2) | 44(54.3) | | |
| High: 75–89 mmHg | 1501(33.1) | 1043(33.2) | 428(32.6) | 30(37.0) | | |

* eGFR estimated glomerular filtration, SD standard deviation, IQR interquartile range, BMI body mass index, HbA1c hemoglobin A1c, LDL low-density lipoprotein, UA uric acid, PP pulse pressure, SBP systolic pressure, DBP diastolic pressure.
combination of high SBP and high PP (OR = 1.79, 95% CI 1.27–2.54) and the combination of low SBP and high PP (OR = 3.07, 95% CI 1.24–7.58) showed significant association with the increased risk of rapid decline of eGFR. (Table 4) Results of unadjusted and partly adjusted models were present in Additional file 2.

Age-stratified analyses showed that the combination of high SBP and high PP (OR = 2.65, 95% CI 1.11–6.33) and the combination of low SBP and normal PP (OR = 1.63, 95% CI 1.10–2.40) were significantly correlated with the increased risk of rapid decline of eGFR among participants aged < 55 years. (Table 4) Results of unadjusted and partly adjusted models were present in Additional file 2.

**Discussion**

To find a risk indicator of decline in kidney function among the general population, the present study investigated the association between BP components and the risk of rapid decline of eGFR based on a nationally representative longitudinal study of middle and old aged general population in China. Significant association was observed between PP, SBP and the risk of rapid decline of eGFR among the middle and old aged general population without hypertension, especially among those younger than 55 years. Higher levels of SBP, although lower than 140 mmHg, and excessively low levels of SBP (< 120 mmHg) were correlated to the increased risk of decline in kidney function. PP showed satisfied performance on the risk prediction of decline in kidney function, and the prognostic significance increased with the combination with high SBP. In sum, as an easily-accessible, cost-saving and non-invasive indicator, it is potentially effective to use PP, SBP, and the combination of SBP and PP to monitor the risk of decline in kidney function among the middle and old aged general population.

Increased PP is caused by the elevated SBP and/or decreased DBP and is the results of multiple mechanisms including deficiency of vascular elastin, deterioration of the windkessel function, and decline of left ventricular function. [16, 23] The elevated SBP results in left ventricular hypertrophy leading to the increased afterload whereas the decreased DBP results in the reduced perfusion of coronary artery. [23] Kidney plays essential roles in the homeostasis of hemodynamics. [41] The kidney perfusion pressure precisely responds to the alteration of arterial circulation and BP, and the kidney further regulates the extracellular volume and BP through multiple mechanisms [41]. As to the middle and old aged general population without hypertension, neither the arterial circulation nor the structure of vascular has obvious dysfunction or injury, but the process of ageing gradually impact the vascular physiology and hemodynamics [9]. Alteration of hemodynamics is an important pathogenesis of chronic injury of kidney [41]. Compared with SBP and DBP, the levels of PP much sensitively reflect the changes of systemic hemodynamics, hence showed better prognostic significance. Previously, Rifkin et al. reported a twofold increased risk of rapid decline of kidney function (eGFR loss ≥ 3 ml/min/year) with the PP > 80 mmHg among the elderly (average age: 72.2 years) based on the Cardiovascular Health Study [26]. The present results demonstrated that PP showed satisfactory performance on predicting the risk of decline in kidney function among the Asians and provided the evidence for the prognostic performance of PP among the middle aged population. Although the mechanism of PP and chronic kidney injury remains to be investigated, the present results suggested the potential effectiveness to use PP and the combination

![Fig. 2 The levels of PP in different BP categories](image-url)
Table 2: Comparison of kidney function among BP categories

| Kidney Function | Overall | PP category | P value | SBP category | P value | DBP category | P value |
|-----------------|---------|-------------|---------|--------------|---------|--------------|---------|
|                 |         | Normal <60 mmHg | High ≥ 60 mmHg | Low < 120 mmHg | Medium 120–129 mmHg | High 130–139 mmHg | Low < 60 mmHg | Medium 60–74 mmHg | High 75–89 mmHg | P value |
| eGFR in 2011 (ml/min/1.73m², mean±SD) | 96.4±15.6 | 970±15.3 | 91.0±16.6 | <0.001 | 97.6±14.9 | 96.0±16.3 | 93.8±16.0 | <0.001 | 95.5±14.8 | 96.3±15.7 | 96.8±15.6 | 0.261 |
| eGFR in 2015 (ml/min/1.73m², mean±SD) | 91.4±17.2 | 922±16.9 | 84.8±18.8 | <0.001 | 92.3±17.0 | 91.5±17.2 | 88.9±17.8 | <0.001 | 89.3±18.7 | 91.0±17.3 | 92.9±16.6 | <0.001 |
| Annual decline of eGFR (ml/min/1.73m², IQR) | −0.9 (−2.8, 0.6) | −0.9 (−2.7, 0.3) | −1.1 (−3.2, 0.3) | 0.013 | −0.9 (−2.9, 0.5) | −0.9 (−2.5, 0.6) | −1.0 (−2.9, 0.8) | 0.013 | −1.0 (−2.9, 0.5) | −1.0(2.9, 0.5) | −0.8 (−2.5, 0.9) | 0.011 |
| Rapid decline of eGFR* (n, %) | 3839(84.7) | 3454(85.1) | 385(80.7) | 2025(84.5) | 1024(86.3) | 4708(83.3) | 2105(84.1) | 444(83.6) | 444(83.6) | 1290(85.9) | 1290(85.9) | 0.011 |

BP: blood pressure, PP: pulse pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, eGFR: estimated glomerular filtration, SD: standard deviation, IQR: interquartile range

* Rapid decline of eGFR was defined as eGFR decline ≥ 4 ml/min/1.73 m²/year
of PP and SBP as a surrogate indicator for the risk monitor of CKD in the general population.

The goal of BP on preservation of kidney function among the general population is not clear yet. Generally, the prevention of hypertension (BP < 140/90 mmHg) is considered as the effective approach for CKD prevention among the general population without pre-existing hypertension [8], while few studies further explored the precise BP threshold for kidney function preservation among this population. Results of Systolic Blood Pressure Intervention Trial (SPRINT) strongly suggested the benefits of intensive BP control (SBP < 120 mmHg) on reducing the risk of cardiac events among patients with hypertension and high-risk of CVD [42]. However, the present study found that SBP lower than 120 mmHg showed risk effects on the preservation of kidney function among the middle and old aged general population, especially among those aged 45 to 54 years. It indicated the goals of BP control among the patients with hypertension and among the general population should be different. For the general population without hypertension, intensively low SBP results in the low perfusion of the kidney, which lead to chronic ischemia, hypoxia, and inflammation. Current clinical guidelines of CKD and BP recommended 130/80 mmHg as the goal of BP control among patients with CKD [10, 12]. The present results demonstrated that this threshold was beneficial for kidney function preservation among the general population, but a lower limit of BP was needed. According to the current results, the level of

### Table 3: Association between BP category and the risk of the rapid decline of eGFR, fully adjusted and age-stratified

| Variables | In total (n, %) | Overall | Age 45–54 years | Age 55–64 years | Age ≥ 65 years |
|-----------|----------------|---------|-----------------|----------------|---------------|
|           | Adjusted OR    | P value | Adjusted OR     | P value        | Adjusted OR   | P value       |
| PP category |                  |         |                 |                |               |
| Normal: < 60 mmHg | 4057(89.5) | Ref | Ref | Ref | Ref |
| High: ≥ 60 mmHg     | 477(10.52)    | 1.34(1.02–1.75) | 0.036 | 1.65(0.83, 3.29) | 0.153 | 1.23(0.79–1.90) | 0.364 | 1.51(1.00–2.27) | 0.051 |
| SBP category |                  |         |                 |                |               |
| Medium: 120–129 mmHg | 1187(26.2) | Ref | Ref | Ref | Ref |
| Low: < 120 mmHg     | 2398(52.9)    | 1.28(1.03–1.59) | 0.025 | 1.65(1.13–2.43) | 0.010 | 1.05(0.76–1.46) | 0.769 | 1.15(0.73–1.81) | 0.550 |
| High: 130–139 mmHg | 949(20.9)     | 1.32(1.02–1.71) | 0.032 | 1.34(0.81–2.22) | 0.255 | 1.41(0.95–2.07) | 0.084 | 1.26(0.78–2.05) | 0.345 |
| DBP category |                  |         |                 |                |               |
| Low: < 60 mmHg     | 531(11.7)     | Ref | Ref | Ref | Ref |
| Medium: 60–74 mmHg | 2502(55.2)    | 0.95(0.72–1.25) | 0.706 | 1.10(0.67–1.82) | 0.708 | 0.99(0.62–1.59) | 0.974 | 0.78(0.48–1.27) | 0.321 |
| High: 75–89 mmHg  | 1501(33.1)    | 0.83(0.62–1.12) | 0.226 | 0.81(0.48–1.38) | 0.446 | 0.96(0.58–1.59) | 0.888 | 0.77(0.44–1.34) | 0.349 |

*Adjusted for age, gender, smoke, drink, BMI, HbA1c, LDL, UA, eGFR at baseline*

BP: blood pressure, PP: pulse pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, OR: odds ratio, Ref: reference, BMI: body mass index, HbA1c: hemoglobin A1c, LDL: low-density lipoprotein, UA: uric acid, eGFR: estimated glomerular filtration rate

### Table 4: Association between types of BP combination and the risk of the rapid decline of eGFR, fully adjusted and age-stratified

| Types of BP combination | In total (n, %) | Overall | Age 45–54 years | Age 55–64 years | Age ≥ 65 years |
|-------------------------|----------------|---------|-----------------|----------------|---------------|
|                         | Adjusted OR    | P value | Adjusted OR     | P value        | Adjusted OR   | P value       |
| BP combination |                  |         |                 |                |               |
| Medium SBP and Normal PP | 1068(23.6) | Ref | Ref | Ref | Ref |
| High SBP or High PP | 739(16.3)     | 0.96(0.72–1.29) | 0.806 | 1.09(0.63–1.89) | 0.746 | 1.01(0.66–1.55) | 0.965 | 0.83(0.45–1.51) | 0.538 |
| High SBP and High PP | 329(7.3)      | 1.79(1.27–2.54) | 0.001 | 2.65(1.11–6.33) | 0.028 | 1.65(0.96–2.84) | 0.069 | 1.66(0.93–2.95) | 0.087 |
| Low SBP and Normal PP | 2369(52.3) | 1.21(0.97–1.51) | 0.094 | 1.63(1.10–2.40) | 0.014 | 0.97(0.70–1.36) | 0.874 | 1.06(0.65–1.75) | 0.796 |
| Low SBP and High PP | 29(0.6)       | 3.07(1.24–7.58) | 0.015 | 14.25(0.92–220.60) | 0.057 | 1.95(0.39–9.86) | 0.418 | 2.90(0.78–10.76) | 0.110 |

*Adjusted for age, gender, smoke, drink, BMI, HbA1c, LDL, UA, eGFR at baseline*

BP: blood pressure, PP: pulse pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, OR: odds ratio, Ref: reference, BMI: body mass index, HbA1c: hemoglobin A1c, LDL: low-density lipoprotein, UA: uric acid, eGFR: estimated glomerular filtration rate
120–129 mmHg was the satisfactory threshold of SBP on CKD prevention among the middle and old aged general population.

The present study has several limitations. Firstly, information of albuminuria was not available in CHARLS cohort, the association between BP and albuminuria was failed to be analyzed. Secondly, subject to the case number of participants with low SBP and high PP, results of the age-stratified analyses in the combination of low SBP and high PP need to be validated in larger population. Thirdly, the observational nature of our study limited the ability to make causal inference. Fourthly, although ethnic-specific association between genes and BP components were demonstrated in previous studies [30–32], the present study did not investigate the association between genetic factors and the BP components subject to the absence of gene data. Lastly, the possibility of residual confounding exists.

Conclusion
PP, SBP and the combination of PP and SBP could be surrogate risk indicator for the rapid decline of kidney function among the middle and old aged general population without pre-existing hypertension. Individuals with high PP, excessively low SBP, or elevated SBP near to the threshold of hypertension should be recognized as the high-risk population of rapid decline of kidney function. Risk monitor, CKD screening, and early prevention should be timely initiated among the high-risk population.

Abbreviations
BP: Blood pressure; BMI: Body mass index; CHARLS: China Health and Retirement Longitudinal Study; CI: Confidence interval; CKD: Chronic kidney disease; CVD: Cardiovascular disease; DBP: Diastolic blood pressure; eGFR: Estimated glomerular filtration rate; HbA1c: Glycosylated hemoglobin; IQR: Interquartile range; LDL: Low-density lipoprotein; OR: Odds ratio; PP: Pulse pressure; SBP: Systolic blood pressure; SCr: Serum creatinine; SD: Standard deviation; UA: Uric acid.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12967-021-03176-8.

Additional file 1. Unadjusted and partly adjusted models for the association between BP category and the risk of rapid decline of eGFR, age-stratified.

Additional file 2. Unadjusted and partly adjusted models for the association between types of BP combination and the risk of rapid decline of eGFR, age-stratified.

Acknowledgements
We appreciate the very kind support from all colleagues of National Institute of Health Data Science at Peking University and coordinators at the data sites for their support.

Authors' contributions
HYW designed the study, interpreted the results, and drafted the manuscript. HYW, CY, QM and YW cleaned and analyzed the data. QM and YW were involved in data collection and data cleaning. GK, YZ and LZ made critical revision of the manuscript for important intellectual content. LZ is the study guarantor. All authors have read and approved the final manuscript.

Funding
This study was supported by grants from the National Natural Science Foundation of China (82100741, 91846101, 81771938, 81301296, 81900665), Beijing Nova Programme Interdisciplinary Cooperation Project (Z1911000119008), the National Key R&D Program of the Ministry of Science and Technology of China (2016YFC1050450, 2019YFC2005000), the University of Michigan Health System-Peking University Health Science Center Joint Institute for Translational and Clinical Research (BMU20160466, BMU2018J012, BMU2019J005), PKU-Baidu Fund (2019BDL017) and from Peking University (BMU2018MX020, PKU2017LCX05).

Availability of data and materials
The data underlying this article are available in the China Health and Retirement Longitudinal Study at http://charls.pku.edu.cn/index/en.html, and can be accessed after application.

Declarations
Ethics approval and consent to participate
This study was approved by the Biomedical Ethics Review Committee of Peking University. All participants gave written informed consent before participation.

Consent for publication
All the authors listed have approved the manuscript for publication.

Competing interests
Luxia Zhang received research funding from AstraZeneca, independent from the present study. The remaining authors have no competing financial interests to declare.

Author details
1 National Institute of Health Data Science, Peking University, 38 Xueyuan Road, Haidian District, Beijing 100191, China. 2 School of Public Health, Peking University, Beijing, China. 3 Institute of Social Science Survey, Peking University, School of Development, Peking University, Beijing, China. 4 Renal Division, Department of Medicine, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing 100034, China. 5 National School of Development, Peking University, Beijing, China.

Received: 13 November 2020 Accepted: 2 December 2021
Published online: 20 December 2021

References
1. Zhang L, Long J, Jiang W, Shi Y, He X, Zhou Z, et al. Trends in chronic kidney disease in China. N Engl J Med. 2016;375(9):905–6.
2. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052–90.
3. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.
4. Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–52.
5. Zhang L, Wang F, Wang L, Wang W, Liu B, Liu J, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815–22.
6. Jha V, Garcia-Garcia G, Isiek I, Li Z, Naicker S, Plattert B, et al. Ionic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260–72.
7. Chen TR, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294–304.
8. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney disease: improving global outcomes—KDIGO evaluation and management 2012. https://kdigo.org/guidelines/ckd-evaluation-and-management/.
9. Hommoos MS, Glasscock RJ, Rule AD. Structural and functional changes in human kidneys with healthy aging. J Am Soc Nephrol. 2017;28(10):2838–44.
10. Williams B, Mancia G, Spiering W, Agabiti Rosselli E, Azzii M, Burnier M, et al. ESC/EAS guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.
11. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/ASCVD/AAPA/ABC/ACP/NMA/AGS/APhA/ASH/ ASCP/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):13–115.
12. KDIGO Guidelines—Blood Pressure in CKD. https://kdigo.org/guidelines/blood-pressure-in-ckd/.
13. Wan EY, Yu EY, Chin WY, Fong DY, Tcho EPH, Lam CLK. Association of blood pressure and risk of cardiovascular and chronic kidney disease in hong kong hypertensive patients. Hypertension. 2019;74(2):331–40.
14. Chang AR, Lören M, Malhotra R, Appel LJ. Blood pressure goals in patients with CKD: a review of evidence and guidelines. Clin J Am Soc Nephrol. 2019;14(1):161–9.
15. Avello AP, Kuznetsova T, Heyndrickx GR, Kerkhof PLM, Li JKJ. Arterial flow, pressure and wave velocity in men and women at various ages. Adv Exp Med Biol. 2018;1065:153–68.
16. Bakris GL, Laffin LJ. Assessing wide pulse pressure: hypertension data beyond the guidelines. J Am Coll Cardiol. 2019;73(22):2856–8.
17. Gillebert TC. Pulse pressure and blood pressure components: is the sum more than the parts? Eur J Prev Cardiol. 2018;25(5):457–9.
18. Safar ME, Plante GE, Mimran A. Arterial stiffness, pulse pressure, and the kidney. Am J Hypertens. 2015;28(5):561–9.
19. Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Casado A, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol. 2006;17(12 Suppl 3):S246–9.
20. Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure. Nat Rev Nephrol. 2012;8(10):602–9.
21. Fernandez-Fresnedo G, Rodrigo E, de Francisco AL, de Castro SS, Casado A, Arias M. Role of pulse pressure on cardiovascular risk in chronic kidney disease patients. J Am Soc Nephrol. 2006;17(12 Suppl 3):S246–9.
22. Mancusi C, Losi MA, Izzo R, Cancello G, Carlino MV, Albano G, et al. Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 2002;287(20):2677–83.
23. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS, et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2019;139(14):1816–25.
24. Zoccali C, Vanholver F, Massy ZA, Ortiz A, Sarafidis P, Dekker FW, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344–58.
25. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort profile: the China Health and Retirement Longitudinal Study (CHARLS). Int J Epidemiol. 2014;43(1):161–8.
26. Chen X, Cimmins E, Hu PP, Kim JK, Meng Q, Strauss J, et al. Venous blood-based biomarkers in the china health and retirement longitudinal study: rationale, design, and results from the 2015 wave. Am J Epidemiol. 2019;188(1):1871–7.
27. Guichard JL, Desai RV, Ahmad M, Mujib M, Fonarow GC, Feller MA, et al. Isolated diastolic hypertension and incident heart failure in older adults. Hypertension. 2011;58(5):895–901.
28. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303(6799):385–9.
29. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
30. Wafei HM, Textor SC. The role of the kidney in regulating arterial blood pressure. Nat Rev Nephrol. 2012;8(10):602–9.
31. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.